Alpha 2.0
Login Register
» Authors » Nicole Basset Seguin

Nicole Basset Seguin

Explore the profile of Nicole Basset Seguin including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 246
Followers 0
Related Specialties
Oncology
Dermatology
Top 10 Co-Authors
Celeste Lebbe
Josep Malvehy
Lars Bastholt
Laurent Mortier
Eduardo Nagore
Veronique Bataille
Cecile Pages
Thomas Jouary
Claus Garbe
Myrto Trakatelli
Published In
Eur J Cancer
Melanoma Res
Br J Dermatol
Eur J Dermatol
Affiliations
Soon will be listed here.
Recent Articles
1.
Genomic profiling of a skin adnexal carcinomas cohort using a comprehensive high-throughput sequencing approach
Louveau B, Nakouri I, Jouenne F, Baroudjian B, Sadoux A, Meda L, et al.
Br J Dermatol . 2024 Jun; 191(4):639-641. PMID: 38836587
No abstract available.
2.
European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023
Peris K, Fargnoli M, Kaufmann R, Arenberger P, Bastholt L, Basset Seguin N, et al.
Eur J Cancer . 2023 Aug; 192:113254. PMID: 37604067
Basal cell carcinoma (BCC) is the most common malignant tumour in white populations. Multidisciplinary experts from European Association of Dermato-Oncology (EADO), European Dermatology Forum, European Society for Radiotherapy and Oncology...
3.
Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial
Veron M, Chevret S, Grob J, Beylot-Barry M, Saiag P, Flechon A, et al.
Eur J Cancer . 2022 Nov; 177:103-111. PMID: 36335780
Background: Basal cell carcinoma (BCC) is the most common human malignancy. In most cases, BCC has slow progression and can be definitively cured by surgery or radiotherapy. However, in rare...
4.
Risk behaviour and patient preferences for an improved non-melanoma skin cancer prevention modality for organ-transplanted patients: a European, multi-country, online patient community study
Basset Seguin N, Malvehy J, Nadal F, Creancier L, Rauly-Lestienne I, Beauchamp R, et al.
Eur J Dermatol . 2019 Oct; 29(5):518-523. PMID: 31647462
Immunosuppressants used in organ transplant patients increase the risk of non-melanoma skin cancer. This study aimed to evaluate patient behaviours towards skin cancer prevention methods and to understand characteristics of...
5.
Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines
Peris K, Fargnoli M, Garbe C, Kaufmann R, Bastholt L, Basset Seguin N, et al.
Eur J Cancer . 2019 Jul; 118:10-34. PMID: 31288208
Basal cell carcinoma (BCC) is the most common malignant tumour in white populations. Multidisciplinary experts from the European Dermatology Forum, the European Association of Dermato-Oncology and the European Organization of...
6.
Anti-programmed cell death protein 1 tolerance and efficacy after ipilimumab immunotherapy: observational study of 39 patients
Amode R, Baroudjian B, Kowal A, Jebali M, Allayous C, Bagot M, et al.
Melanoma Res . 2016 Dec; 27(2):110-115. PMID: 27926587
In patients with ipilimumab (IPI)-refractory melanoma, the anti-programmed cell death proteins 1 (PD1s) nivolumab (NIV) and pembrolizumab (PEM) are considered to be a new standard of treatment. Few data are...
7.
BRAF inhibitor rechallenge in patients with advanced BRAF V600-mutant melanoma
Roux J, Pages C, Malouf D, Basset Seguin N, Madjlessi N, Baccard M, et al.
Melanoma Res . 2015 Sep; 25(6):559-63. PMID: 26397052
In around 50% of melanomas, the BRAF V600 mutation, resulting in an activation of the MAP kinase pathway, is detected. BRAF inhibitors have shown remarkable activity on the disease. However,...